Good business performance with significant growth in Core EBITDA: Core Net Sales €215.4 MM (+5% year-on-year) and Core EBITDA €68.0MM (+46% year-on-year)

Growth drivers momentum continues. Ilumetri® sales growing c.+90% year-on-year, Klisyri® launched successfully in the US in February 2021 and Seysara® modest rebound in line with the overall OAB market

Gianfranco Nazzi joined as Almirall’s new CEO on May 1st, 2021. His international experience and expertise in executing product launches will enable the company to deliver its global strategy and carry on the strategic roadmap

Innovative pipeline with significant value still to be unlocked: expected upcoming approvals of Klisyri® and Wynzora® in Europe in Q2 2021, and lebrikizumab phase 3 ongoing with headline readout expected in H2 2021

Based on the good start of the year-to-date performance, Almirall is reiterating its 2021 Guidance

Solid Core Q1 performance boosted by Growth Drivers and included some one-time items with positive impact on Net Sales for €16 MM in Q1 2021.

Read more